Important Role of Soluble Epidermal Growth Factor receptor levels in the Patients with Breast Cancer

Human EGF is a 1406-Da protein with 65 amino acid residues and three Intra molecular disulfide bonds. EGF acts by binding with high affinity to epidermal growth factor receptor (EGFR) on the cell surface and stimulating the intrinsic protein-tyrosine kinase activity of the receptor. The tyrosine kinase activity, in turn, initiates a signal transduction cascade that results in a variety of biochemical changes within the cells, increased glycolysis and protein synthesis, and increases inthe expression of certain genes including the gene for EGFR - that ultimately lead to DNA synthesis and cell proliferation. Many proteins are proteolytically released from the surface by a process known as ectodomain shedding. A variety of integral membrane protein, including EGFRcan be released from the lipid bilayer by proteolysis to from soluble, truncated proteins. In 2412, itis estimated that there were more than 2.8 million women living in the US with a history of invasive breast cancer, and an additional 221,924 women will be diagnosed. Growth factorsincluding epidermal growth factor plays important role in the development of breast cancer. Theaim of this study was to determine the total protein concentration (TPC) and levels of solube EGFR(sEGFR) in the serum of patients with breast cancer by enzyme linked immune sorbent assay(ELISA). No significant change in TPC has been seen in the serum of patients with breast cancer ascompared to normal controls. However, It was also shown that the concentration of serum sEGFR in the patients with breast cancer is higher than in normal control. The data from this study indicate that sEGFRis a constant component of human serum and high levels of serum sEGFR may be partly related to the pathophysiology of breast cancer

کلیدواژه ها:

Soluble epidermal growth factor receptor ، concentration ، serum ، breast cancer